Generic Name: clobetasol propionate

Brand Name: Olux Foam 0.05%, Olux-E Foam 0.05%

Medication Class: topical corticosteroid

FDA Approved Uses: Olux: Short-term topical treatment of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the scalp and short term treatment of mild to moderate plaque-type psoriasis on non-scalp regions

Olux-E: Short-term topical treatment of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses

Available Dosage Forms: 0.05% foam; 50 gm and 100 gm cans

Usual Doses: Apply twice daily, morning and evening. Total dosage should not exceed 50 gm per week (for Olux-E: 50 gm or 21 capfuls).

Duration of Therapy: 2 consecutive weeks. Therapy should be discontinued when control is achieved.

Approximate cost (based on AWP 2008): Olux (100gm) $287.39 Olux-E (100gm) $287.39

Criteria for Use: (bullet points below are all inclusive unless otherwise noted)
- For Olux: Clinically documented corticosteroid-responsive dermatoses of the scalp or mild to moderate plaque-type psoriasis on non-scalp regions
- For Olux-E: Clinically documented corticosteroid-responsive dermatoses
- Must be 12 years of age or older
- Must have tried for a minimum of 2 weeks and failed all of the following:
  - clobetasol (Temovate) cream, gel, ointment, or solution for scalp application. And
  - At least two other formulary very high potency or high potency topical steroids.

Cautions: Clobetasol propionate is a highly potent topical corticosteroid and has been shown to suppress the HPA axis at the lowest doses tested.
Contraindications:
- Hypersensitivity to clobetasol propionate, to other corticosteroids, or to any ingredient in the preparation

Not approved if:
- Patient does not meet the above stated criteria.
- Patient has any contraindications to the use of clobetasol or corticosteroids.
- Being used on the face, groin, axillae or other intertriginous areas
- Being used in the treatment of rosacea or perioral dermatitis

Notes:
- Olux is marketed as ideal for the scalp, is ethanol based, and is marketed as non-drying and non-hydrating
- Olux-E is marketed as ideal for the body, is an ethanol-free emollient formulation (but does include cetyl alcohol), and is marketed as soft and moisturizing

Step therapy Requirements:
- Topical clobetasol* and topical betamethasone** and topical fluocinonide

*Excludes Clobex products, Olux and Olux-E
** Excludes Luxiq

P&T Approval: ____________________________ Date: ______________